- Home
- VRPX vs SYRS Comparison
VRPX vs SYRS Comparison
Compare VRPX & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- SYRS
- Stock Information
- Founded
- VRPX 2016
- SYRS 2011
- Country
- VRPX United States
- SYRS United States
- Employees
- VRPX N/A
- SYRS N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- SYRS Health Care
- Exchange
- VRPX Nasdaq
- SYRS Nasdaq
- Market Cap
- VRPX 6.0M
- SYRS 5.7M
- IPO Year
- VRPX 2021
- SYRS 2016
- Fundamental
- Price
- VRPX $0.26
- SYRS $0.17
- Analyst Decision
- VRPX Hold
- SYRS Hold
- Analyst Count
- VRPX 1
- SYRS 5
- Target Price
- VRPX N/A
- SYRS $3.00
- AVG Volume (30 Days)
- VRPX 8.8M
- SYRS 1.1M
- Earning Date
- VRPX 03-25-2025
- SYRS 03-26-2025
- Dividend Yield
- VRPX N/A
- SYRS N/A
- EPS Growth
- VRPX N/A
- SYRS N/A
- EPS
- VRPX N/A
- SYRS N/A
- Revenue
- VRPX N/A
- SYRS $386,000.00
- Revenue This Year
- VRPX N/A
- SYRS N/A
- Revenue Next Year
- VRPX N/A
- SYRS N/A
- P/E Ratio
- VRPX N/A
- SYRS N/A
- Revenue Growth
- VRPX N/A
- SYRS N/A
- 52 Week Low
- VRPX $0.23
- SYRS $0.16
- 52 Week High
- VRPX $5.48
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- VRPX 40.47
- SYRS 38.78
- Support Level
- VRPX $0.25
- SYRS $0.16
- Resistance Level
- VRPX $0.47
- SYRS $0.20
- Average True Range (ATR)
- VRPX 0.04
- SYRS 0.02
- MACD
- VRPX 0.00
- SYRS 0.01
- Stochastic Oscillator
- VRPX 4.86
- SYRS 35.75
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.